2023, Number 6
<< Back Next >>
Med Int Mex 2023; 39 (6)
Thymic carcinoma
Heredia RB, Heredia TB, Campos CG, Padilla PI, Sevilla LDB
Language: Spanish
References: 11
Page: 948-954
PDF size: 374.26 Kb.
ABSTRACT
Background: Thymus carcinoma is a very rare neoplasm with adverse prognosis,
it is part of the epithelial neoplasms of the thymus, which also includes thymoma.
Clinical case: A 75-year-old male patient, referred to the internal medicine service
for preoperative evaluation for knee arthroplasty, during the anamnesis the presence
of B symptoms was referred, the chest X-ray showed mediastinal widening without
displacement. Computed tomography showed an occupational lesion of 9.2 x 7.0 x
8.1 cm in the anterior mediastinum.
Conclusions: This case is interesting as it is a rare entity in the world literature
since in the United States a prevalence lesser than 2% of all malignant neoplasms is
reported. There are 13 subtypes of thymic carcinoma, 70% of which correspond to
the squamous cell subtype.
REFERENCES
Tseng Yau-Lin. Thymic carcinoma: A rare cancer requiringspecial attention. Formosan J Surg 2011; 44: 136-140. Doi:10.1016/j.fjs.2011.08.007.
Roden AC, Szolkowska M. Common and rare carcinomas ofthe thymus. Virchows Arch 2021; 478 (1): 111-128. https://doi.org/10.1007/s00428-020-03000-6.
Syrios J, Diamantis N, Fergadis E, Katsaros L, Logothetis M,Iakovidou I, Lianos E, Grivas A, Athanasiou AE. Advancesin thymic carcinoma diagnosis and treatment: a reviewof literature. Medical Oncol 2014; 31 (7): 44. https://doi.org/10.1007/s12032-014-0044-2.
Calabrese F, Fortarezza F, Pezzuto F, Lunardi F, ComacchioG, Sbaraglia M, Pasello G, Marulli G, Dei Tos A, et al. Therarest of rare thymic lesions: A 10-year surgical pathologyexperience. Cancers 2021; 13 (16): 4056. https://doi.org/10.3390/cancers13164056.
Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymicmalignancies: from clinical management to targeted therapies.J Clin Oncol 2011; 29 (36): 4820-4827. https://doi.org/10.1200/JCO.2011.36.0487.
Rendina EA, Venuta F, De Giacomo T, Ciccone AM, MorettiMS, Ibrahim M, Coloni GF. Biopsy of anterior mediastinalmasses under local anesthesia. Ann Thorac Surg 2002; 74 (5): 1720-1723. https://doi.org/10.1016/s0003-4975(02)03821-3.
Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, HarrisNL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K,Orazi A, Ströbel P. The 2015 World Health OrganizationClassification of Tumors of the Thymus: Continuity andChanges. J Thoracic Oncol 2011; 10 (10): 1383-1395.https://doi.org/10.1097/JTO.0000000000000654
Yokoyama S, Miyoshi H. Thymic tumors and immunecheckpoint inhibitors. J Thorac Dis 2018; 10 (Suppl 13):S1509-S1515. https://doi.org/10.21037/jtd.2017.10.157
Kitadai R, Okuma Y. Future perspective of chemotherapyand pharmacotherapy in thymic carcinoma.Cancers 2021; 13 (20): 5239. https://doi.org/10.3390/cancers13205239
Cabezón-Gutiérrez L, Khosravi-Shahi P, Custodio-CabelloS, García-Martos M, Palka-Kotlowska M, Franco-MorenoAI. Metastatic thymic carcinoma with long survival aftertreatment with sunitinib. Cureus 2018; 10 (7): e2982.https://doi.org/10.7759/cureus.2982
DeVita Vincent T Jr, Lawrence T, Rosenberg SA. Devita,Hellman, and Rosenberg's Cancer: Principles & Practice ofOncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Full text